Related by context. All words. (Click for frequent words.) 72 AEZS 70 ARRY 69 CRx 69 CUDC 69 AEGR 66 histone deacetylase HDAC inhibitor 66 ITMN 64 ganetespib 64 BAY #-# 64 HCV protease inhibitor 64 Hsp# inhibitor 64 4SC 64 ALTU 63 ISIS # 63 ALKS 63 MGCD# [001] 63 Traficet EN 63 OXi# 63 orally bioavailable 63 Mipomersen 63 VQD 63 RGB # 63 INGN 63 MT# MEDI 63 ATHX 63 Bezielle 62 Dapagliflozin 62 PRTX 62 investigational compound 62 JAK inhibitor 62 Perifosine 62 HGS ETR1 62 pomalidomide 62 elotuzumab 62 MEK inhibitor 62 cannabinor 62 MAP# 62 ENMD 62 polymerase inhibitor 62 HuMax CD# 61 phase IIb clinical 61 HuMax CD4 61 TELINTRA 61 pan HDAC inhibitor 61 PS# [001] 61 forodesine 61 IPL# 61 PDE4 inhibitor 61 PEG SN# 61 investigational drug 61 IMMU 61 novel topoisomerase 61 oral prodrug 61 Laquinimod 61 ALGRX 61 axitinib 61 mertansine 61 mapatumumab 61 ADXS# 61 T DM1 61 PRX # 60 talactoferrin 60 eniluracil 60 ELND# 60 RDEA# 60 Archexin 60 CoFactor 60 alvespimycin 60 enzastaurin 60 selective androgen receptor modulator 60 Omacetaxine 60 PF # [001] 60 dacetuzumab 60 CCX# 60 KRN# 60 obatoclax 60 humanized monoclonal antibody 60 preclinical 60 Amrubicin 60 Nanobody 60 Azilect ® 60 Nexavar ® 60 SCH # 60 anidulafungin 60 investigational oral 60 CIMZIA TM 60 renin inhibitor 60 MAGE A3 ASCI 60 IDX# 60 HCV protease inhibitors 60 PSMA ADC 60 HGS# 60 tanespimycin 60 Bicifadine 60 YONDELIS 60 EndoTAG TM -1 60 ADX# 60 iCo 59 telaprevir VX 59 Ozarelix 59 oral FTY# 59 PEGylated irinotecan 59 investigational humanized monoclonal antibody 59 methylnaltrexone 59 lumiliximab 59 EOquin 59 proteasome inhibitor 59 celgosivir 59 ProSavin 59 IMGN# 59 HuLuc# 59 MORAb 59 CD# antibody [001] 59 OMNARIS HFA 59 bicifadine 59 Asentar 59 ACHN 59 INCB# [001] 59 Pazopanib 59 ELACYT 59 PRT# 59 PEG Interferon lambda 59 AEG# 59 Telcyta 59 LymphoStat B 59 amrubicin 59 atacicept 59 BiTE 59 Vidofludimus 59 PSN# [002] 59 tezampanel 59 elagolix 59 glufosfamide 59 relapsed multiple myeloma 59 Serdaxin 59 Voreloxin 59 radiation sensitizer 59 PNP inhibitor 59 targeting CD# 59 Carfilzomib 59 liposomal formulation 59 XL# [003] 59 RhuDex ® 59 NVA# 59 xenograft models 59 Phase Ib study 59 INCB# [002] 59 Staccato loxapine 59 evaluating tivozanib 59 Guanilib 59 Phase 2a trial 59 Panzem 59 aflibercept 59 Cethromycin 59 injectable formulation 59 HZT 58 IMC A# 58 lixivaptan 58 Harbor BioSciences 58 TREANDA 58 imatinib mesylate 58 ADP receptor antagonist 58 HuMax EGFr 58 AP# [003] 58 initiate Phase 1b 58 Oral NKTR 58 epothilone 58 Dalbavancin 58 perifosine 58 Targretin 58 Sym# 58 Phase Ib 58 Hedgehog pathway inhibitor 58 rNAPc2 58 orally administered inhibitor 58 GRN# 58 ATL# [001] 58 prodrug 58 MNTX 58 sorafenib tablets 58 Phase Ib clinical trials 58 CCR9 antagonist 58 peripherally acting 58 huC# DM4 58 DDP# 58 Elagolix 58 Epothilone D 58 docetaxel Taxotere R 58 EZN 58 Synavive 58 Aclidinium 58 Inhalation Solution 58 Tesetaxel 58 sorafenib Nexavar 58 NGX# 58 AVONEX ® 58 ANG# 58 Aplidin 58 histone deacetylase inhibitor 58 CORT # 58 Debio 58 CA4P 58 ularitide 58 Panzem R 58 antiplatelet agent 58 Azedra 58 bafetinib 58 retapamulin 58 ANX 58 preclinical efficacy 58 oritavancin 58 investigational compounds 58 CCR5 antagonist 58 seliciclib CYC# 58 pertuzumab 58 otelixizumab 58 JAK2 inhibitor 58 Phase 2a clinical 58 TOCOSOL Paclitaxel 58 Aflibercept 58 sapacitabine 58 lesinurad 58 MEK inhibitors 58 Tyrima 58 panitumumab Vectibix 58 Phase IIa clinical 58 belinostat 58 Anticalin R 58 Symadex 58 Tarceva TM 58 oral antiviral 58 tesmilifene 58 metaglidasen 58 TriRima 58 Ixempra 58 oral formulation 58 PROMACTA 58 Alpharadin 58 virus HCV protease inhibitor 58 Indaflex TM 58 TELCYTA 58 phase IIb 57 CEQ# 57 ocrelizumab 57 phase IIa clinical 57 Menerba 57 ALN TTR 57 diabetic neuropathic pain 57 orally administered 57 Tarvacin 57 reslizumab 57 JANUVIA 57 Azixa 57 SERMs 57 nucleoside analog 57 epothilones 57 AQ4N 57 INNO 57 Æterna Zentaris 57 voreloxin 57 ISTODAX 57 vascular disrupting agent 57 Phase IIb trial 57 OncoVEX GM CSF 57 nucleotide analog 57 Pimavanserin 57 taxane 57 Phase 2b clinical 57 PXD# 57 LY# [002] 57 HCV NS5B polymerase 57 Darusentan 57 drug conjugate 57 Aurora kinase 57 Nanobody ® 57 adipiplon 57 systemic RNAi therapeutic 57 ARQ 57 tesetaxel 57 MEDI 57 Allovectin 7 R 57 lintuzumab 57 vinca alkaloid 57 sodium glucose cotransporter 57 non nucleoside inhibitor 57 visilizumab 57 Maribavir 57 Zolinza 57 Peregrine Pharmaceuticals 57 cathepsin K inhibitor 57 Telaprevir 57 DAVANAT 57 ATL/TV# 57 Herceptin trastuzumab 57 brentuximab vedotin SGN 57 docetaxel Taxotere ® 57 HGS ETR2 57 XOMA 57 Rebif ® 57 Onconase 57 carfilzomib 57 R roscovitine 57 Alocrest 57 Safinamide 57 CYC# 57 TBC# 57 Prednisporin 57 Phase 1b 57 vidofludimus 57 Vilazodone 57 SRT# [003] 57 ixabepilone 57 darapladib 57 IAP inhibitor 57 humanized anti 57 RVX 57 generation Hsp# inhibitor 57 VAPRISOL 57 QVA# 57 Civacir 57 GSK# [001] 57 Zelrix 57 HER2 positive metastatic breast 57 Phase 2a 57 JAK1 57 Phase IIa trial 57 Phase IIb clinical 57 selective androgen receptor modulators 57 NXL# 57 AAG geldanamycin analog 57 MGCD# [002] 57 integrase inhibitor 57 HSP# inhibitor 57 Zalbin 57 antisense drug 57 FTY# 57 alvimopan 57 GLPG# 57 ponatinib 57 gefitinib Iressa 57 Radezolid 57 Ridaforolimus 57 Panzem R NCD 57 Corlux 57 Hsp# inhibitors 57 Phase Ib clinical 57 investigational monoclonal antibody 57 lomitapide 57 KSP inhibitor 57 Vicriviroc 57 Lorianne Masuoka MD 57 bendamustine 57 velafermin 57 transcriptase inhibitor NNRTI 57 preclinical studies 57 Belinostat 57 Reverset 57 OHR/AVR# 57 Viramidine 57 Sapacitabine 56 CIMZIA ™ 56 TYZEKA 56 CYT# 56 LY# [003] 56 Cannabinor 56 Myocet 56 Zenvia Phase III 56 receptor tyrosine kinase inhibitor 56 refractory gout 56 IAP inhibitors 56 Milnacipran 56 Lacosamide 56 CXA 56 ACTEMRA TM 56 phase IIa 56 standard chemotherapy regimen 56 REMOXY ® 56 telbivudine 56 VEGF Trap 56 inhibitor RG# 56 Cleviprex TM clevidipine 56 Hsp# Inhibitor 56 Trastuzumab 56 Unit Dose Budesonide 56 Cloretazine ® 56 Progenics Pharmaceuticals 56 entinostat 56 Thiarabine 56 alfimeprase 56 Ambrisentan 56 pradefovir 56 phase IIb trial 56 Immunogen 56 Ocrelizumab 56 vascular disrupting agents 56 small molecule tyrosine 56 SinuNase 56 Xyfid TM 56 demonstrated antitumor activity 56 Golimumab 56 BiTE antibody 56 Phase 2b study 56 Clay B. Siegall 56 BMN 56 fostamatinib 56 Eltrombopag 56 huN# DM1 56 Phase IIa 56 daclizumab 56 Factor VIIa 56 novel anticancer 56 anti amnesic 56 dexamethasone Decadron 56 TG# [003] 56 antitumor activity 56 signal transduction inhibitor 56 kinase inhibitor 56 ketolide antibiotic 56 Anthim 56 BIBW 56 dose cohorts 56 LymphoStat B TM 56 Blinatumomab 56 Ceflatonin 56 elvucitabine 56 mipomersen 56 picoplatin 56 Neulasta ® 56 Phase IIb 56 vinorelbine 56 Abiraterone acetate 56 long acting muscarinic 56 PHX# 56 Phase 2b 56 BZL# 56 aprepitant 56 Xanafide 56 TKM ApoB 56 safinamide 56 CERE 56 oral bioavailability 56 stated Michelle Berrey 56 generation antisense 56 XL# XL# XL# 56 TYKERB 56 Aurexis 56 Romidepsin 56 proteasome inhibitors 56 MLN# 56 teduglutide 56 Ceflatonin R 56 LHRH antagonist 56 Pradefovir 56 Tezampanel 56 AEterna 56 Allovectin 7 56 Aliskiren 56 DP b# 56 novel histone deacetylase 56 Nektar Therapeutics NKTR 56 ulimorelin 56 rilonacept 56 cilengitide 56 ENMD # 56 pivotal Phase III 56 docetaxel chemotherapy 56 Triolex 56 posaconazole 56 Panitumumab 56 FluCide 56 GW# [003] 56 deforolimus 56 palonosetron 56 SAR# [004] 56 Ophena TM 56 Hycamtin 56 radezolid 56 histone deacetylase HDAC 56 CYT# potent vascular disrupting 56 APTIVUS r 56 Ron Bentsur 56 brivaracetam 56 GnRH antagonist 56 BCX# 56 FOLOTYN ® 56 eltrombopag 56 Actilon 56 ceftazidime 56 Phenoptin 56 Treanda 56 veltuzumab 56 ZOLINZA 56 Rexahn Pharmaceuticals 56 Phase #b/#a clinical 56 Elesclomol 56 Capesaris 56 Tasimelteon 56 AZILECT R 56 Erlotinib 56 iroxanadine 56 Onrigin 56 PI3K/Akt pathway inhibitor 56 Vicinium TM 56 ALN PCS 56 ISENTRESS 56 NASDAQ LGND 56 immunomodulator 56 CD3 monoclonal antibody 56 lexidronam injection 56 Synta Pharmaceuticals 56 RSD# 56 InNexus Biotechnology 56 Arqule 56 anticancer compound 56 AVE# 56 imatinib Gleevec ® 56 mTOR inhibitor 56 apremilast 56 cetuximab Erbitux ® 56 DOS# 56 metastatic hormone refractory 56 immunotherapeutic agent 56 Apoptone 56 HspE7 56 bortezomib Velcade ® 56 Atiprimod 56 sitaxsentan 56 bazedoxifene 56 IMC #B 56 antithrombotic 56 CR# vcMMAE 56 nucleoside analogue 56 EndoTAG 56 anticancer agent 56 metastatic castration resistant 56 diarrhea predominant irritable 55 Irinotecan 55 elacytarabine 55 Relivar 55 mGluR5 negative 55 targeted radiotherapeutic 55 GlaxoSmithKline plc GSK 55 LibiGel ® 55 SARMs 55 XmAb# 55 Phase IIa trials 55 ApoB SNALP 55 monotherapy 55 Tanespimycin 55 HDAC inhibitor 55 INC# 55 administered subcutaneously 55 VELCADE melphalan 55 PrevOnco 55 NP2 Enkephalin 55 Peregrine Pharmaceuticals Inc. 55 tezampanel NGX# 55 ONTAK 55 KSP inhibitors 55 bevirimat 55 PEG INTRON 55 CCX# B 55 alagebrium 55 registrational 55 INT# [002] 55 Hana Biosciences 55 Phase Ib II 55 BAL# [002] 55 intranasal formulation 55 Velcade bortezomib 55 QLT# 55 Levetiracetam 55 Avanafil 55 Daclizumab 55 Marqibo 55 CINTREDEKIN BESUDOTOX 55 bortezomib Velcade R 55 PREZISTA r 55 Phase III clinical 55 IMiDs 55 ASONEP 55 Aerosurf 55 volociximab 55 bosutinib 55 dirucotide 55 desvenlafaxine 55 tasocitinib 55 Lupuzor 55 PCK# 55 Telaprevir VX 55 Vernakalant 55 BNC# 55 MTP inhibitor 55 Amplimexon 55 nicotinic alpha 7 55 CDP# 55 APOPTONE 55 Allovectin 7 ® 55 oral ridaforolimus 55 ozarelix 55 ThermoDox R 55 Telavancin 55 Zoraxel 55 Cardio Vascu Grow 55 preclinically 55 Arcalyst 55 Cloretazine 55 NASDAQ OPTR 55 anti TNF alpha 55 therapeutic antibody 55 AZILECT ® 55 JVRS 55 Phase 2a Clinical Trial 55 Lu AA# 55 EGFR inhibitors 55 Talabostat 55 HDAC Inhibitor 55 PI3K inhibitor 55 tolerability profile 55 zanolimumab 55 HQK 55 Preclinical 55 fluoropyrimidine 55 trabectedin 55 IL# PE#QQR 55 DPP4 inhibitor 55 BRIM2 55 rhIGF-I/rhIGFBP-3 55 #ME# 55 ESBA# 55 DOXIL 55 IV Busulfex 55 Phase IIa clinical trials 55 orally dosed 55 EOquin TM 55 remission induction 55 DB# [003] 55 dasatinib Sprycel 55 Cetrorelix 55 Tarvacin TM 55 2 methoxyestradiol 55 phase Ib 55 rFIXFc 55 Fc fusion protein 55 midstage clinical 55 Phase #/#a trial 55 Nexavar 55 betrixaban 55 CEROVIVE NXY 55 aclidinium 55 REP# 55 valopicitabine 55 mu opioid receptor antagonist 55 Icatibant 55 clinical pharmacology studies 55 #D#C# 55 Vitaxin 55 oncolytic 55 anti leukemic 55 GALNS 55 Varespladib 55 Tamibarotene 55 interferon beta 1b 55 inhaled formulation 55 tremelimumab 55 Rajesh C. Shrotriya 55 ZYBRESTAT 55 R#/MEM # 55 XYOTAX TM 55 HIV integrase inhibitors 55 thymalfasin 55 darinaparsin ZIO 55 SUVN 55 Cyclooxygenase Inhibiting Nitric Oxide 55 Locteron 55 lorvotuzumab mertansine 55 TMC# [002] 55 Nexavar sorafenib 55 sunitinib malate 55 milatuzumab 55 non nucleoside HCV 55 GLYX 55 Phase 2b Clinical Trial 55 BPAX 55 Phase 1b clinical 55 selective kinase inhibitor 55 angiogenesis inhibitor 55 teriflunomide 55 Xeloda ® 55 xanthine oxidase inhibitor 55 Molecular Insight 55 Oxytrex TM 55 SCY 55 pharmacokinetic properties 55 XYOTAX 55 Cimzia TM 55 Dasatinib 55 Sanctura XR 55 Zometa zoledronic acid 55 ThermoDox ® 55 rasagiline tablets 55 bortezomib 55 Trofex 55 multi kinase inhibitor 55 SAR# [002] 55 Troxatyl 55 Bortezomib 55 Chrysalin 55 Vion Pharmaceuticals 55 Initiate Phase 55 anti TNF 55 Chemophase 55 R#/MEM 55 alfa 2a 55 Axitinib 55 non nucleoside 55 ALN TTR# 55 DermaVir Patch 55 renin inhibitors 55 cetuximab Erbitux R 55 Zingo TM 55 HRPC 55 tumor vascular disrupting 55 LT NS# 55 nucleoside reverse transcriptase inhibitor 55 ridaforolimus 55 Lixivaptan 55 Seliciclib 55 CD# monoclonal antibody 55 fosbretabulin 55 INKP 55 Alfimeprase 55 Phase IIb trials 55 motavizumab 55 ostarine 55 cangrelor 55 leading oral taxane 55 LAF# 55 riociguat 55 AZD# 55 DU #b 55 perampanel 55 ANAVEX #-# [003] 54 Rasagiline 54 LibiGel Phase III 54 VA# [002] 54 sodium thiosulfate STS 54 phase 2a 54 Fibrillex TM 54 CGEN # 54 DXL# 54 Nasdaq OPTR 54 Virulizin ® 54 subcutaneous formulation 54 CK # novel 54 OPAXIO 54 Ofatumumab 54 cetuximab Erbitux 54 Gabapentin GR 54 TRO# 54 Copegus ribavirin 54 BRAF inhibitor 54 motesanib diphosphate 54 Atrasentan 54 Homspera 54 vemurafenib 54 sulodexide 54 Regeneron Pharma 54 iSONEP 54 Apricus Bio 54 acting muscarinic antagonist 54 Cinquil 54 iobenguane 54 custirsen 54 edoxaban 54 Relovair 54 seliciclib 54 bicalutamide 54 II Clinical Trial 54 PEGylated Fab fragment 54 μg dose 54 PARP inhibitor 54 INCB# [003] 54 cancer immunotherapies 54 Phase #/#a 54 Gemin X 54 Eribulin 54 RELOVAIR ™ 54 Preclinical studies 54 HCV polymerase inhibitors 54 SPC# [001] 54 ZEVALIN ® 54 HCV protease 54 Saxagliptin 54 NASDAQ CLDX 54 Eraxis 54 PKC# 54 diabetic nephropathy 54 PD LID 54 CytoFabTM 54 novel immunomodulatory 54 oral Hsp# inhibitor 54 MEK Inhibitor 54 sunitinib 54 Fibrin Pad 54 investigational 54 vilazodone 54 XL# XL# 54 oral proteasome inhibitor 54 inhaled liposomal ciprofloxacin 54 Aegerion 54 Zalicus 54 Zybrestat 54 alemtuzumab Campath 54 GSK# [002] 54 dalbavancin 54 pharmacodynamic properties 54 GSK '# 54 relapsed refractory multiple myeloma 54 Phase 1b trial 54 XL# XL# XL# XL# 54 favorable pharmacokinetic profile 54 SPRYCEL ® 54 Interferon alpha 54 Meets Primary Endpoint 54 ONX 54 TRX1 54 Vaprisol 54 temsirolimus 54 Telintra 54 bevacizumab Avastin 54 Vandetanib 54 Satraplatin 54 talabostat 54 dose cohort 54 Ecallantide 54 bortezomib Velcade 54 Metabasis Therapeutics Inc. 54 Keryx Biopharmaceuticals 54 trastuzumab DM1 T DM1 54 immunomodulating 54 OMP #M# 54 ORMD 54 dyskinesia PD LID 54 nucleoside analogues 54 DVAX 54 Exherin TM 54 mTOR inhibitors 54 Phase 2b trial 54 cobiprostone 54 ALN RSV# 54 Entremed 54 Acadia Pharmaceuticals 54 BARACLUDE ® 54 Personalized Immunotherapy 54 neratinib 54 Celsion Corporation 54 ORENCIA R 54 vosaroxin 54 hA# 54 paclitaxel poliglumex 54 Arimidex anastrozole 54 Pivotal Phase III 54 Albuferon 54 DAVANAT R 54 Aurora Kinase 54 indacaterol 54 GRN#L 54 tafamidis 54 atrasentan 54 NS#/#A protease 54 TNF Tumor Necrosis Factor 54 KNS # 54 PEG PAL 54 prasugrel CS 54 bevacizumab Avastin ® 54 Annamycin 54 imetelstat 54 Virulizin 54 depsipeptide 54 VentiRx 54 squalamine 54 Genentech Roche 54 intravenously administered 54 generation antisense inhibitor 54 triphendiol 54 Xinlay 54 dextromethorphan quinidine 54 ofatumumab 54 goserelin 54 maribavir 54 Biogen Idec NASDAQ BIIB 54 Aeolus Pharmaceuticals 54 transdermal spray 54 Tesmilifene 54 davunetide intranasal AL 54 Gleevec imatinib mesylate 54 RAPTIVA 54 octreotide acetate 54 ceftaroline 54 Trexima 54 IRX 2 54 opioid induced bowel dysfunction 54 satraplatin 54 levodopa induced dyskinesia 54 Seattle Genetics SGEN 54 dexpramipexole 54 GSK # 54 BMS # 54 IV APAP 54 Enhanze Technology 54 ImmunoVEX HSV2 54 Genasense oblimersen sodium Injection 54 Tolvaptan 54 pemetrexed Alimta 54 torezolid phosphate 54 BCR ABL inhibitors 54 NASDAQ SNTA 54 EVIZON TM 54 Immunomedics Inc 54 LBH# 54 iniparib 54 Dificid 54 CBLC# 54 Ventavis 54 VEGF inhibitors 54 romidepsin 54 ProLindac 54 Zerenex ™ 54 Tocosol Paclitaxel 54 cyclophilin inhibitor 54 APD# 54 Parkinson disease levodopa induced 54 Entereg 54 oral JAK1 54 TLR8 agonist 54 Genz # 54 cediranib 54 HCV polymerase inhibitor 54 regorafenib 54 Pertuzumab 54 Novelos 54 Bremelanotide 54 LE SN# 54 Nanobodies 54 zalutumumab 54 Nasulin 54 LEUKINE 54 synthetic retinoid 54 elinogrel 54 CoTherix 54 ARIKACE 54 registrational studies 54 farletuzumab 54 Dyloject TM 54 RDEA 54 Nasdaq VRTX 54 PrevOnco ™ 54 RG# [001] 54 resolvin 54 Diabetic Macular Edema 54 multitargeted 54 erlotinib Tarceva ® 54 IMiD 54 PEGylated 54 Ramoplanin 54 Staccato alprazolam 54 NexACT 54 TTF Therapy 54 antiviral activity 54 NASDAQ REGN 54 Bucindolol 54 mitogen activated ERK kinase 54 Sulonex 54 Pixantrone 54 Ziopharm 54 Methylnaltrexone 54 midstage studies 54 pan histone deacetylase 54 delafloxacin 54 docetaxel 54 CombinatoRx Incorporated NASDAQ CRXX 54 CCR2 54 nitazoxanide 54 Clonicel 54 ongoing Phase 1b 54 Crizotinib 54 Randomized Phase 54 ONCONASE 54 CRLX# 54 endothelin receptor antagonists 54 ON #.Na 54 RG# ITMN 54 DepoMed 54 mGluR5 NAM 54 HepeX B 54 selective modulator 54 QNEXA 54 Exelixis XL#